Ymmunobio and EVIIVE announce collaboration to develop advanced liquid biopsy for detecting NPTXR in cancer patients

We are thrilled to announce a groundbreaking partnership between Ymmunobio and EVIIVE to advance the future of cancer diagnostics!

Together, we are developing an innovative liquid biopsy technology using extracellular vesicles (EVs), enhancing precision in disease detection and monitoring. Our joint efforts will leverage Ymmunobio's cutting-edge biotechnological expertise and EVIIVE's advanced diagnostic platforms to create a revolutionary tool in the fight against cancer. 

Ymmunobio and EVIIVE are pioneering advances in diagnostics and oncology, working towards a future where healthcare is more personalized, precise, and effective for all patients.

Stay tuned for more updates as we work towards a brighter, healthier future!

Read the full press release here:

Ymmunobio is proud to announce our ASCO publication on YB-800

We are thrilled to announce that Ymmunobio's abstract has been published in the American Society of Clinical Oncology (ASCO) annual conference publications:

"YB-800, a monoclonal antibody targeting the human neuronal pentraxin receptor (NPTXR), as a potential candidate for the design of a first-in-class antibody-drug conjugate (ADC) as a novel therapeutic intervention in gastro-intestinal cancers"

The full publication can be found here.

The abstract highlights using a fully humanized monoclonal antibody, YB-800, directed against the human neuronal pentraxin receptor (NPTXR). The expression of NPTXR has been associated with disease progression in several GI Cancers, including gastric, esophageal, colorectal, pancreatic, bladder and liver as well as breast and thyroid cancer. These findings provided a strong rationale for the design of a YB-800 based ADC, offering a novel therapeutic intervention option for patients with high unmet medical needs.

We are thrilled to contribute to the advancement of cancer treatment and dedicated to pursuing innovative therapies that can significantly impact patient care.

Ymmunobio has been selected for the Venture Leaders Biotech 2024!

We are very proud to announce that Ymmunobio is one of 10 Start-ups that has been selected for the Venture Leaders Biotech 2024.

Selected from over 70 applicants by a jury of investors and biotech experts, Ymmunobio will join the roadshow in Boston, one of the world's most important life science hubs. From May 13th - 17th 2024, the roadshow will connect the participants with international investors and industry leaders, accelerating their ventures' expansion the US.

Go to the Venture Leaders Biotech Website for more information.